• No results found

SAHLGRENSKA AKADEMIN INSTITUTIONEN FÖR BIOMEDICIN

N/A
N/A
Protected

Academic year: 2021

Share "SAHLGRENSKA AKADEMIN INSTITUTIONEN FÖR BIOMEDICIN"

Copied!
2
0
0

Loading.... (view fulltext now)

Full text

(1)

Göteborg, 2020

SAHLGRENSKA AKADEMIN INSTITUTIONEN FÖR BIOMEDICIN

Impact of Genetic Variants in Inosine Triphosphate Pyrophosphatase and Interferon-λ4 on Natural History, Treatment Response and Ribavirin Pharmacology in Hepatitis C Virus Infection

Akademisk avhandling

som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin, Göteborgs universitet kommer att offentligen försvaras i föreläsningssal Arvid Carlsson, Medicinaregatan 3, fredagen den 15 maj 2020, klockan 09.00.

av Jesper Waldenström Fakultetsopponent:

Clas Ahlm, professor

Institutionen för klinisk mikrobiologi, Umeå universitet, Sverige Avhandlingen baseras på följande delarbeten

I. Rembeck K, Waldenström J, Hellstrand K, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Lagging M. Variants of the Inosine Triphosphate Pyrophosphatase Gene are Associated with Reduced Relapse Risk Following Treatment for HCV Genotype 2/3.

Hepatology. 2014;59(6):2131-9.

II. Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkila M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Buhl MR, Stenmark S, Lagging M. Randomized Trial Evaluating the Impact of Ribavirin MonoTherapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. PLoS One. 2016;11(5):e0155142.

III. Nystrom K, Wanrooij PH, Waldenstrom J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang K, Lagging M. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. J Virol. 2018;92(19).

IV. Waldenstrom J, Kåberg M, Alanko-Blomé M, Widell A, Björkman P, Nilsson S, Hammarberg A, Weiland O, Nyström K, Lagging M. Interferon-λ4 Genetic Variants are Independently Associated with Spontaneous Clearance of Acute Hepatitis C Virus Genotype 1-3 Infection, and Inosine Triphosphate Pyrophosphatase Polymorphisms Impact on Immune Responses in Men. In Manuscript.

(2)

Göteborg, 2020

Impact of Genetic Variants in Inosine Triphosphate Pyrophosphatase and Interferon-λ4 on Natural History, Treatment Response and Ribavirin Pharmacology in Hepatitis C Virus Infection

Jesper Waldenström

Avdelningen för infektionssjukdomar, Institutionen för biomedicin, Sahlgrenska akademin, Göteborgs universitet, Sverige, 2020.

Abstract

Hepatitis C virus (HCV) impacts on global health with around 70 million chronically infected worldwide. The infection increases the risk of cirrhosis and primary liver cancer. The treatment until 2013 has been based on interferon-α and ribavirin, but is now replaced by direct acting antivirals. Ribavirin is still used in the most difficult-to- cure patients. This thesis evaluates host genetic variations in inosine triphosphate pyrophosphatase (ITPA) and interferon-λ4 (IFNL4) in relation to cure rates in patient treated with interferon-α and ribavirin as well as ribavirin pharmacology in the setting of chronic HCV infection, and spontaneous resolution of acute HCV infection. In a post-hoc analysis of 354 HCV genotype 2/3 infected patients receiving interferon-α and ribavirin, genetic variation in ITPA entailing reduced ITPase activity was associated with increased cure rates (paper I). Small inhibiting RNA aimed at ITPA reduced ITPase levels and increased the antiviral effect of ribavirin, ribavirin

associated viral mutations and concentrations of ribavirin triphosphate intracellularly, in vitro. ITPase was also shown to be able to dephosphorylate ribavirin triphosphate (paper III). In a randomized trial, standard interferon-α and ribavirin treatment was compared to four weeks ribavirin monotherapy prior to combination treatment and to two weeks of ribavirin double dosage alongside with interferon-α. Both experimental strategies succeeded in reaching high ribavirin concentrations at earlier timepoints in dual therapy. Ribavirin monotherapy resulted in a viral decline associated with IFNL4 genotype (paper II). IFNL4 genotype was associated with clearance in acute HCV genotype 1 as well as in genotype 2/3 infection. ITPA genotype showed significant associations with age at seroconversion and spontaneous resolution in males with favorable IFNL4 genotype (paper IV).

Keywords: Hepatitis C virus, HCV, Inosine triphosphate pyrophosphatase, ITPA, interferon-λ4, IFNL4, ribavirin, interferon, PWID, IP-10.

ISBN 978-91-7833-844-3 (PRINT) http://hdl.handle.net/2077/62223 ISBN 978-91-7833-845-0 (PDF)

References

Related documents

To clarify whether baseline intrahepatic IP-10 mRNA expression reflects baseline plasma IP-10 levels in predicting first phase viral decline and sustained

IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV.. Lagging M,

In the NORDynamIC study with 354 peg-IFNα2a and RBV treated chronic HCV genotype 2 or 3 infected patients, we were able to demonstrate that SNPs in ITPA reducing the activity

2020 Impact of Genetic V ariants in Inosine T riphosphate Pyrophosphatase and Interferon- λ4 on Natur al History , Treatment Response and Ribavirin Pharmacology in Hepatitis C

genetic variants of PNPLA3, IL28B and ITPA, on liver disease severity and treatment outcome in HCV genotype 2 and 3 infected patients treated with pegylated interferon and

[r]

Secondary glaucoma and visual outcome after paediatric cataract surgery with primary bag-in-the-lens intraocular lens.. Alf Nyström, Birgitte Haargaard, Annika Rosensvärd,

Previous studies have shown that grade of inflammation as well as stage of fibrosis in 1-year protocol biopsies of the liver graft to be predictive of fibrosis